Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes specialty pharmaceuticals and other health products. The company operates across multiple therapeutic areas and reports financial results under IFRS. Takeda generates a significant portion of its revenue from markets outside Japan, with substantial exposure to USD, EUR, CNY, BRL, and RUB currencies. The company focuses on both organic growth through new product launches and pipeline development, as well as strategic acquisitions. Takeda utilizes a transformation program to drive cost savings and operational efficiency, and manages a substantial debt portfolio following its acquisition of Shire. The company maintains hybrid subordinated bond instruments and actively manages its leverage ratio, targeting deleveraging through adjusted free cash flow generation. Takeda's R&D efforts span late-stage pipeline programs, and its product portfolio is subject to loss-of-exclusivity dynamics, including the conclusion of VYVANSE amortization. The company also maintains strategic partnerships including a global partnership agreement with Innovent Biologics and arrangements with Protagonist Therapeutics. Updated Jul 30, 2026